Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus MACROTEC.
GALLIUM GA 68 GOZETOTIDE vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
Not applicable for diagnostic use.
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical